Sign In
Buy CLRB
$2.57
+0.0400 (+1.58%)
At Close: Jul 31, 2026
Cellectar to Participate in the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
04:01pm, Wednesday, 15'th Sep 2021
FLORHAM PARK, N.J., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs fo
Cellectar Receives $2M NIH Grant For Rare Lymphoma Study
11:54am, Wednesday, 18'th Aug 2021
Cellectar Biosciences Inc (NASDAQ: CLRB) has received a peer-reviewed National Institutes of Health (NIH) Phase II Small Business Innovation Research (SBIR) grant of approximately $2 million from t
Cellectar Awarded $2.0 Million Phase II NIH SBIR Grant to Support Pivotal Study of Iopofosine I-131 in Waldenstrom's Macroglobulinemia
08:30am, Wednesday, 18'th Aug 2021
FLORHAM PARK, N.J., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for
Cellectar Announces Manufacturing and Supply Agreement with Evergreen Theragnostics for CLR-131, now known as iopofosine I-131
08:30am, Monday, 16'th Aug 2021
Evergreen to provide clinical and commercial supply of iopofosine I-131 (also known as CLR 131)
Cellectar Reports Financial Results for the Second Quarter 2021 and Provides a Corporate Update
08:30am, Monday, 09'th Aug 2021
FLORHAM PARK, N.J., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for
Cellectar Announces Expansion of Ongoing Collaboration Agreement with IntoCell Inc.
09:00am, Tuesday, 13'th Jul 2021
Preclinical Data Supports Further Development of Multiple Novel Phospholipid Drug Conjugates (PDCs) Preclinical Data Supports Further Development of Multiple Novel Phospholipid Drug Conjugates (PDCs)
Cellectar, LegoChemBio Team Up To Develop Phospholipid Drug Conjugates For Solid Tumors
11:00am, Monday, 12'th Jul 2021
Cellectar Biosciences Inc (NASDAQ: CLRB) has collaborated with LegoChemBio to develop and commercialize phospholipid drug conjugates (PDCs). Under the agreement, the two companies have the option t
Development of Multiple Novel PDCs Development of Multiple Novel PDCs
Cellectar to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference
08:30am, Thursday, 08'th Jul 2021
FLORHAM PARK, N.J., July 08, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for
Cellectar Announces the Election of Dr. Asher Alban Chanan-Khan to Its Board of Directors
08:30am, Thursday, 24'th Jun 2021
FLORHAM PARK, N.J., June 24, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for
Cellectar Bio Stock Drops After ASCO Presentation on White Blood Cell Cancer Therapy
03:13pm, Friday, 04'th Jun 2021
Cellectar Biosciences Inc (NASDAQ: CLRB) announced updated data at the American Society of Clinical Oncology (ASCO) Annual Meeting from Phase 2 CLOVER-1 study of CLR 131 in relapsed/refractory B-ce
Cellectar to Participate at the Oppenheimer Rare & Orphan Disease Summit on May 21, 2021
09:00am, Friday, 14'th May 2021
FLORHAM PARK, N.J., May 14, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for
Cellectar Reports Financial Results for the First Quarter 2021 and Provides a Corporate Update
08:30am, Monday, 10'th May 2021
Initiated pivotal study of CLR 131 in Waldenstrom's macroglobulinemia (WM) Received European Orphan Drug Designation for CLR 131 in WM
New patent covers phospholipid-ether analogs combined with various small molecule chemotherapeutics and methods of use for PDCs™ New patent covers phospholipid-ether analogs combined with various sm
Cellectar to Participate at Upcoming Institutional Investor Conferences
08:30am, Thursday, 11'th Mar 2021
FLORHAM PARK, N.J., March 11, 2021 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercia
